Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 an...(ams; our planned Phase 2clinical studies...)

Date:10/8/2008

ams; our planned Phase 2 clinical studies and the ability of those studies to successfully evaluate HspE7 as a potential treatment for CIN 1 and CIN 2/3; the structure and location of our planned Phase 2 trials; completion of the second protocol for CIN 1; potential uses for Poly-ICR; our ability to advance Poly-ICR resulting in revenue generation and internal development; the ability of Poly-ICR to provide us with near-term revenue opportunity; the development of Poly-ICR for treatment of GW and actinic keratosis; completion of development activities and the filing of an IND application in connection with Poly-ICR; finalizing manufacturing and formulation protocols and filing an IND in connection with Hsp 6/11; execution of our corporate restructuring as planned; our ability to retain key personnel; and our plan to expand corporate development efforts and the potential results of such efforts.

Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments to be materially different from results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, the possibility that our planned corporate restructuring will not have the anticipated affect; that we will not succeed in forming strategic alliances and, if we do, the possibility that such alliances will not allow us to realize the greatest value for our programs; that we will not commence Phase 2 clinical studies as planned and, if we do, that such studies will not support the use of HspE7 as a treatment for CIN 1 or CIN 2/3; that we will not complete the second protocol for the CIN 1 indication; that Poly-IRC will not be useful as a broad immune stimulatory agent or vaccine adjuvant; that we will not be able to advance Poly-ICR to generate revenue or for internal development; that Poly-ICR will not provide us with near-term reve
'/>"/>

SOURCE Nventa Corporation Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. Nventa Appoints Gordon H. Busenbark to Board of Directors
10. CardioDynamics Provides 2007 Shareholder Meeting Update
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update